acalabrutinib + itraconazole

Outputting this combination name implies a clinical scenario rather than a single marketed product. It refers to the concomitant administration of **acalabrutinib**, a selective, covalent inhibitor of Bruton tyrosine kinase (BTK), and **itraconazole**, an azole antifungal agent. Acalabrutinib is primarily indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Itraconazole is indicated for the treatment of a range of systemic and superficial fungal infections. The principal pharmacological relevance of this combination is the significant drug–drug interaction: itraconazole, a strong inhibitor of CYP3A, markedly increases the exposure of acalabrutinib, which is metabolized predominantly by CYP3A. This leads to increases in acalabrutinib plasma concentrations and risk of adverse events, necessitating clinical caution and potential dose adjustment of acalabrutinib[2][3][4][5].

Other names

acalabrutinibitraconazole